Vitae's Drug Potential 'Significant,' Stifel Upgrades To Buy
March 17, 2016 at 09:53 AM EDT
Stifel’s Thomas Shrader upgraded the rating for Vitae Pharmaceuticals Inc (NASDAQ: VTAE) from Hold to Buy, with a price target ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.